Benefits of a dual sagittal crystal transducer for ultrasound imaging during I-125 seed implantation for permanent prostate brachytherapy

Emmie Kaljouw, MSc1, Bradley Pieters, MD, PhD1, Kees Kaoedooder, PhD1, Cees Lucas, PhD2, Cara Koning, MD, PhD1
1Department of Radiation Oncology, Academic Medical Center/University of Amsterdam, 2Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Academic Medical Center/University of Amsterdam, The Netherlands

Abstract

Purpose: To investigate whether a longer sagittal view and less movement using a dual sagittal crystal probe (DSCP) for trans rectal ultrasound (TRUS) allow for more accurate online-planning in I-125 permanent implant brachytherapy of the prostate, compared to a single sagittal crystal probe (SSCP).

Material and methods: Between March 2008 and March 2010, 50 patients with prostate cancer were consecutively included in the study. The first 25 of these patients had both their pre- and online-planning based on a single sagittal crystal probe (SSCP). The treatment-plans of the other 25 patients were based on a DSCP TRUS. Three weeks after implantation a post-planning was made based on CT. TRUS online and CT post-plan dose-volume histogram (DVH) parameters, D90 and V100, were compared for both groups. Also, the post-plan DVH parameters of SSCP were compared to DSCP. The possible factors that might influence the post-plan D90 and V100 were analysed using Analysis of Variance (ANOVA).

Results: SSCP and DSCP online mean D90 and V100 were significantly larger than post-plan mean D90 and V100 (P < 0.01). The post-plan mean D90 and mean V100 were both non-significantly larger for SSCP based post-plans compared to DSCP based post plans (P = 0.76 and P = 0.68). ANOVA showed significant impact of prostate volume on the post-plan D90 and V100.

Conclusions: The advantages of the dual sagittal crystal probe did not lead to more accurate online planning by investigating DVH-parameters. The only factor found to have influence on the DVH-parameters was the prostate volume.

J Contemp Brachyther 2012; 4, 3: 141-145
DOI: 10.5114/jcb.2012.30680

Key words: prostatic neoplasms, brachytherapy, computer assisted radiotherapy planning, transrectal ultrasound, D90, V100.

Purpose

In permanent I-125 seed implants of the prostate, the quality of the implant depends, amongst other factors, on the quality of the image modality used during implantation. The image modality most frequently used in the Operation Room (OR) is transrectal ultrasound (TRUS), although other modalities like Computed Tomography (CT) and Magnetic Resonance Imaging (MRI) have also been introduced and are still under investigation [1]. TRUS is most often used, because it is available in the OR and it visualizes the prostate, surrounding tissues, the inserted needles and seeds. TRUS makes online-planning possible, while the brachytherapy treatment-planning can be updated continuously, based on the actual placement of the seeds in the prostate. This is useful, because the online treatment plan can be continuously adjusted, with the patient still positioned in lithotomy position and under general anesthesia, until the dose constraints are met. These features cannot be performed with CT based post-planning, because it is too late to instantly correct for an implant of low quality.

These advantages make further improvement of TRUS based treatment-planning possible. For this purpose Ali et al. [2], compared pre- and post-implant TRUS and CT based plans for I-125 prostate brachytherapy, using a twister mode. The twister mode acquires longitudinal projections of the prostate by rotating the probe over an angular range. There are several advantages of the twister mode, compared to the stepper mode. The possibility of reconstruction of the slices with variable slice thickness (1 to 5 mm) causes better visualization of the seeds. Another advantage is the rotation of the probe instead of the movement through the rectum. This twister mode enabled evaluation during the implant
procedure with soft tissue contrast superior to CT, taking account of oedema and enabling adjustment of the online treatment plan if needed. Since March 2009 a new TRUS probe is used in the Academic Medical Center (AMC, Amsterdam) for prostate brachytherapy. This probe has two sagittal crystals, with a transversal crystal in between, instead of the conventional single sagittal crystal with a transversal crystal in the front (Fig. 1.). The probe has several advantages. Not only a longer sagittal view of the prostate can be seen with the two sagittal crystals, but the position of the crystals also enables a switching from the transversal to the sagittal mode without moving the probe in craniocaudal direction. These advantages were expected to diminish the movement of prostate and surrounding tissues caused by craniocaudal movement of the probe, enabling better projection of the planning target volume (PTV) and organ at risk (OAR) contours and more accurate seed placement.

A retrospective cohort study was conducted to compare the treatment plans based on a single sagittal crystal probe (SSCP) and based on a dual sagittal crystal probe (DSCP). It was hypothesized that the new probe (DSCP) would improve the quality of the online-planning. As a consequence, CT post-planning was expected to be more comparable with TRUS online-planning with DSCP compared to SSCP. To investigate whether the overall quality of post-planning in the new situation had improved, the CT based plans were also compared for both groups.

The primary objective of this study was to investigate whether DSCP allows for more accurate dose planning in I-125 permanent implant brachytherapy than SSCP. Dose Volume Histogram (DVH) parameters of TRUS online-plans were compared to CT post-plans for both the SSCP and the DSCP groups to investigate the similarity of both plans, assuming CT-based plan evaluation as the quality standard. The secondary objective was to determine whether the post-plan based DVH parameters have improved with the DSCP technique compared to the SSCP technique. The investigated DVH parameters are D90 which is the minimal dose received by 90% of the prostate volume and the V100 being the volume of the prostate receiving 100% of the prescribed dose.

### Table 1. Summary of studies

<table>
<thead>
<tr>
<th>Study</th>
<th># Pt</th>
<th># Seeds (activity/seed)</th>
<th>Prostate volume TRUS</th>
<th>Prostate volume CT</th>
<th>Time between implant and CT</th>
<th>D90 post-TRUS</th>
<th>D90 CT</th>
<th>V100 post-TRUS</th>
<th>V100 CT</th>
<th>V100 post-TRUS</th>
<th>V100 CT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acher [3]</td>
<td>49</td>
<td>68 (43-128), 28.8 MBq (39.9-39.9)</td>
<td>40 cm³, mean (SD 14)</td>
<td>40 and 30 cm³, mean</td>
<td>4 weeks</td>
<td>168 Gy, mean</td>
<td>155.5 Gy, mean</td>
<td>96%, mean</td>
<td>91.5%, mean</td>
<td>91.5%, mean</td>
<td></td>
</tr>
<tr>
<td>Kaplan [4]</td>
<td>45</td>
<td>37.7 cm³ mean (20 pt extra seeds)</td>
<td>35.4 cm³, mean</td>
<td>35.5 cm³, mean</td>
<td>4-8 weeks</td>
<td>125.8%, mean</td>
<td>133.6%, mean</td>
<td>97.4%, mean</td>
<td>97.4%, mean</td>
<td>97.4%, mean</td>
<td></td>
</tr>
<tr>
<td>Igidbashian [5]</td>
<td>127, 125</td>
<td>63 (37-98), 0.45 mCi (0.39-0.65)</td>
<td>38.0 mL (14.0-74.4), median</td>
<td>28 days</td>
<td>172 Gy, median (SD 16.0)</td>
<td>155 Gy, median (SD 27.42)</td>
<td>98%, median (SD 6.82)</td>
<td>94%, median (SD 7.52)</td>
<td>94%, median (SD 7.52)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chauveinc [9]</td>
<td>450, 1125</td>
<td>35.11 cm³ (13-80.1 cm³), mean post implant volume</td>
<td>Mean CT/TRUS volume ratio 108 (0.85-2.15)</td>
<td>2 months</td>
<td>183.3 Gy (165-225 Gy), mean</td>
<td>183.5 Gy (115-240 Gy), mean</td>
<td>99.66% (91.5-100%), mean</td>
<td>97.44% (89.45-99.97%), mean</td>
<td>97.44% (89.45-99.97%), mean</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stone [10]</td>
<td>77, 1-125</td>
<td>39.8 cm³ mean (16.6-87.8)</td>
<td>43.6 cm³ mean (17.6-95.6)</td>
<td>1 month</td>
<td>110%, mean</td>
<td>113%, mean</td>
<td>83.1%, mean</td>
<td>87.9%, mean</td>
<td>87.9%, mean</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chew [11]</td>
<td>19</td>
<td>73 (55-104)</td>
<td>36.37 cm³ (mean, postplan TRUS)</td>
<td>3126 cm³ (mean)</td>
<td>1 month</td>
<td>165.89 Gy, mean</td>
<td>171.20 Gy, mean</td>
<td>95.04%, mean</td>
<td>90.43%, mean</td>
<td>90.43%, mean</td>
<td></td>
</tr>
<tr>
<td>Ohashi [12]</td>
<td>412</td>
<td>22.1 mL, mean (6.2-49.6)</td>
<td>24.7 mL, mean (7.8-53.3)</td>
<td>30 days</td>
<td>118.8% (89.4-143.5), mean (SD 6.6)</td>
<td>119.2%, mean (79.4-152.1), mean (SD 11.3)</td>
<td>97.2% (80.7-100), mean (SD 2.0)</td>
<td>96.8% (73.8-100), mean (SD 3.1)</td>
<td>96.8% (73.8-100), mean (SD 3.1)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
of that magnitude can occur between online- and post-plan D_90 (Table 1) [3-5]. Our study therefore involved reviewing 50 intra- and post-operative plans of patients who underwent a permanent I-125 implant of the prostate between March 2008 and March 2010. 25 patients were implanted based on the use of a SSCP (Hitachi, Japan) and 25 on the use of a DSCP (Best Medical Systems, USA). Patients were included with histologically confirmed adenocarcinoma of the prostate eligible for I-125 brachytherapy treatment in AMC (see Table 2). No patient had previous antiandrogen therapy. Patients with a metal hip prosthesis were excluded.

Online-planning

In the OR the patients received general anaesthesia and were positioned in lithotomy position with a Foley balloon catheter inserted into the bladder. The TRUS probe was positioned in the rectum and TRUS images were acquired with an axial slice thickness of 1 mm. The clinical target volume consisted of the prostate. The urethra and rectum were delineated without any margins. All volumes were delineated every 5 mm. The treatment-planning program, Permanent Seed Implant Dosimetry 4.2 (D&K Technologies, Germany), was used for preplanning. Dose volume parameters constraints used for treatment-planning were D_90-prostate > 168.5 Gy (117% of the 144 Gy reference dose [Dref]), V_100 > 95% of V_prostate, D_0.1ml urethra < 120% of Dref, D_0.1ml rectum < 80% of Dref. Between 32 and 75 I-125 seeds were implanted per patient, with a nominal activity of 18.5 MBq/seed. During the implantation the calculated dose distribution was continuously updated based on the actual seed positions as seen on TRUS. If seeds were difficult to identify, the dose update was based on the position of the needle. The updated plan was considered to be the online-plan. At the end of the procedure, based on the online treatment plan, it was decided whether it was necessary to add one or more seeds at positions where an underdosage was observed.

Post-planning

Three weeks after implantation a CT scan (Lightspeed 16 PRO, General Electric, USA) of the prostate was made, with a slice thickness of 3 mm. No Foley balloon catheter was used. Between June 2010 and August 2010 all CT scans of the patients being treated between March 2008 and March 2010 were delineated and post-plans were made randomly. Two observers were blinded for treatment date and type of TRUS used for the implant. The prostate and rectum were delineated. Disagreements between the observers were resolved by consensus, to avoid variation in contouring that would influence the result of DVH-parameters calculations. No formal quantitative analysis for disagreement was used, but rather a discussion on the contouring. Seeds were marked and a post operative plan was made. D_90-prostate, V_100-prostate and D_0.1ml-rectum were calculated.

Statistical analysis

DVH parameters for both groups were analyzed to see if there was a significant difference between the online- and post-planning, based on the two TRUS probes. A paired t-test was used comparing the D_90 of the online- and post-planning and a non-paired t-test was used to compare the

| Table 2. Patient characteristics and DVH parameters |
|----------------------------------|-----------------|-----------------|
|                                  | Value, SSCP group | Value, DSCP group |
| Age at time of treatment, mean (SD) | 65.80 years (5.54) | 64.12 years (8.77) |
| Online plan (TRUS) prostate volume, mean (SD) | 38.67 cc (9.46) | 29.88 cc (8.28) |
| Post plan (CT) prostate volume, mean (SD) | 36.10 cc (8.64) | 27.99 cc (8.13) |
| Number of needles, median (range) | 23 (12-29) | 18 (15-28) |
| Number of seeds in online plan, median (range) | 59 (44-70) | 50 (32-75) |
| Number of seeds in post plan, median (range) | 59 (44-70) | 50 (32-74) |
| D_90 online plan (TRUS), mean (SD) | 170.12 Gy (14.19) | 167.94 Gy (11.13) |
| D_90 post plan (CT), mean (SD) | 149.53 Gy (20.03) | 147.64 Gy (23.33) |
| V_100 online plan (TRUS), median (range) | 99.1% (91.5-99.1%) | 99.3% (97.7-99.9%) |
| V_100 post plan (CT), median (range) | 93.1% (64.7-98.4%) | 90.1% (56.8-99.6%) |
post-plan \(D_{90}\) of the SSCP technique with the post-plan \(D_{90}\) of the DSCP technique. The \(V_{100}\) values were non-normal distributed and therefore a Wilcoxon signed rank test was used comparing the \(V_{100}\) parameters of the online- and post-planning and a Mann-Whitney U test comparing the post-plan \(V_{100}\) parameters of the SSCP technique to the \(V_{100}\) parameters of the DSCP technique.

Possible factors that could have influenced the post-plan \(D_{90}\) or \(V_{100}\) were: the prostate volume, number of needles, number of seeds and age. Therefore, patients were divided into three equally sized groups for each of these factors, to facilitate analysis of variance (ANOVA). The analysis started with all factors included and one after another the least significant factor was removed from the model. Statistical analysis was performed with Statistical Package for the Social Sciences 16.0 (SPSS, IL, USA).

Results

Table 2 shows the prostate volume, \(D_{90}\) and \(V_{100}\) resulting from the online- and post-plan for both SSCP and DSCP. The prostate volumes in the SSCP group are larger than the volumes in the DSCP group. The mean difference is 8.79 ml for the online-plan and 8.11 ml for the post-plan volume. The number of needles and seeds used for implantation depend on the prostate volume and are therefore also a little higher in the SSCP group. The prostate volume had a mean difference of 2.57 ml (SSCP) and 1.89 ml (DSCP) between online- and post-planning, with a larger prostate drawn on TRUS images compared to CT. In six cases one seed from the online-planning could not be identified in the post-planning.

Primary outcomes

Both for SSCP and DSCP, the online mean \(D_{90}\) was statistically significantly larger than the post-plan mean \(D_{90}\) (\(P < 0.01\)). For SSCP this difference for the \(D_{90}\) was 20.6 Gy and for DSCP it was 20.3 Gy. SSCP online- and post-plan mean \(V_{100}\) differed 7.4% whereas for DSCP the difference was \(V_{100}\) 9.9% (both \(P < 0.01\)) (Table 2).

Secondary outcomes

The post-plan mean \(D_{90}\) and mean \(V_{100}\) were both statistically non-significantly higher for the SSCP based post-plans compared to DSCP based post-plans, being 1.89 Gy and 3%, respectively (\(P = 0.76\) and \(P = 0.68\)) (Table 2).

Possible factors that influence post-plan \(D_{90}\) or \(V_{100}\)

ANOVA showed statistically significant impact of prostate volume on the post-plan \(D_{90}\). Age, number of seeds and number of needles had no significant impact. Post hoc tests showed significant difference between the group with the largest prostate volume in the OR (mean \(D_{90}\) of 158.97 Gy) compared to the group with the intermediate (\(D_{90}\) of 145.27 Gy) and smallest prostate volume (\(D_{90}\) of 141.08 Gy). For prostate volume on CT, the group with the intermediate prostate volume had the highest \(D_{90}\) (155.41 Gy), while the group with the smaller prostate volume had a \(D_{90}\) of 141.84 Gy, and 148.11 Gy for the larger prostate volume group. ANOVA indicated that prostate volume in the OR was the only factor having impact on the post-plan \(V_{100}\).

The post hoc test showed statistically significant difference between the group with the largest (\(V_{100}\) of 93.85%) compared to the group with the smallest prostate volume (\(V_{100}\) of 86.96%).

Discussion

The advantages of the DSCP, as mentioned in the introduction, were expected to result in improved quality of the online and post-plans. To investigate the impact of DSCP on the implant quality, 50 patients were consecutively selected for this study. The patients were selected in a period when the brachytherapy team performing the implant was stable, with the same group of people making the treatment plans and implanting the prostate. Therefore, the quality of the online-plans was expected to be comparable for all 50 patients. Results for both \(D_{90}\) and \(V_{100}\) of the online- and post-plan were reported. By using both parameters a representative description of the dose distribution was obtained.

Despite the use of a new TRUS probe, a significant difference between the intra and post operative planning \(D_{90}\) and \(V_{100}\) was seen for both SSCP and DSCP based treatment plans. When considering the online-plan, the standard deviation (SD) of the \(D_{90}\) of SSCP and DSCP were 14.2 Gy and 11.1 Gy and the \(V_{100}\) ranged from 91.5 to 99.1% and from 97.7-99.9%, respectively. The post-plan SD of the \(D_{90}\) was 20.0 Gy for SSCP and 23.3 Gy for DSCP, respectively, while post-plan ranges for \(V_{100}\) were 64.7-98.4% and 56.8-99.6%, respectively. The online-plan \(D_{90}\) and \(V_{100}\) in the DSCP group were very similar among the patients. However, the post-plans were less comparable among the patients for both the SSCP and the DSCP group, indicating that the differences between the post-plans do not predominantly depend on the prostate movement during implantation as was hypothesized. Other factors are playing a major role in this respect. Although stranded seeds were used, the seeds might still migrate after implantation [6]. This could be an explanation for the more comparable online-plans with DSCP, but less comparable post-plans.

The use of the DSCP probe not only failed to result in post-plans with less variation among the patients, but also did not lead to a difference in \(D_{90}\) and \(V_{100}\) values compared to the SSCP probe. The only factor having significant influence on the DVH1 parameters \(D_{90}\) and \(V_{100}\) was the prostate volume, with larger prostate volumes resulting in higher \(D_{90}\) and \(V_{100}\) values on the post-planning 3 weeks after the implant. Prostate volume is therefore a more important factor determining the resulting dose to the prostate than the type of TRUS probe used. Prostate movement due to insertion of the needles is another factor influencing the quality of the implant. Because the prostate movement due to insertion of the needles was the same for both types of TRUS probes used, this might explain why no differences in \(D_{90}\) and \(V_{100}\) values of the two groups were found.

The retrospective study caused the prostate volumes to be unequally divided over the SSCP and DSCP groups, with the SSCP group containing larger prostates and the DSCP
The most important factor found to influence DVH-parameters was the prostate volume.

References